Antifibrillatory efficacy of ersentilide, a novel beta-adrenergic and Ikr blocker, in conscious dogs with a healed myocardial infarction.

@article{Adamson1998AntifibrillatoryEO,
  title={Antifibrillatory efficacy of ersentilide, a novel beta-adrenergic and Ikr blocker, in conscious dogs with a healed myocardial infarction.},
  author={P. Adamson and E. Vanoli and S. S. Hull and R. Foreman and P. Schwartz},
  journal={Cardiovascular research},
  year={1998},
  volume={40 1},
  pages={
          56-63
        }
}
OBJECTIVES IKr blockade is ineffective in preventing ventricular fibrillation elicited by the interaction between acute myocardial ischemia and elevated sympathetic activity. This depends in part on the fact that adrenergic activation offsets more than 50% of the action potential prolonging effect of IKr blockade, and thus impairs its primary mechanism of action. This study examined the antifibrillatory effect of ersentilide (CK-3579), a novel antiarrhythmic agent which combines blockade of the… Expand
Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility
New antiarrhythmic agents for atrial fibrillation.
Cardiac autonomic neural remodeling and susceptibility to sudden cardiac death: effect of endurance exercise training.
  • G. Billman
  • Medicine
  • American journal of physiology. Heart and circulatory physiology
  • 2009
Chapter 104 – New Antiarrhythmic Drugs
...
1
2
...

References

SHOWING 1-10 OF 25 REFERENCES
The electrophysiologic effects of ersentilide on canine hearts.
Antiarrhythmic and antifibrillatory actions of the beta adrenergic receptor antagonist, dl-sotalol.
The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent.
...
1
2
3
...